Phospho-ERBB2 (Tyr1112) AntibodyСпецификацияОбъем | 100 мкл | Синонимы | C-erbB-2, NGL, NEU proto-oncogene, MLN 19, | Клональность | Polyclonal Antibody | Организм | Human | uniprot | P04626 | Иммуноген | Peptide sequence around phosphorylation site of tyrosine 1112 (Q-R-Y(p)-S-E) derived from Human HER2. | Источник | Rabbit | Видовая специфичность | Human, Mouse, Rat | Применение | ELISA, WB,WB:1:500-1:1000 | Примечание | <p>Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.<br/><br/>Chuang TD, et al. (2010)J Biol Chem 285, 23598-606 <br />Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Mol Cancer 8, 94 <br />Thelemann A, et al. (2005) Mol Cell Proteomics 4, 356-76</p> | Клональность1 | Polyclonal | Изотип | IgG | Коньюгат | Non-conjugated | Буффер | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. | Форма | liquid | Хранение | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. | Метод очистки | Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide. | Абревеатура | Phospho-Tyr1112 | Области исследований | Cancer,Tags & Cell Markers,Immunology,Signal transduction | Ссылка на страницу на сайте производителя | ссылка | Western blot analysis of extracts from HepG2 tissue using HER2 (Phospho-Tyr1112) antibody.The lane on the right is treated with the antigen-specific peptide.
| | |
Информация для заказаОбласть использования: | Производство: | Cusabio | Метод: | Антитела | Объем: | 100 мкл | Кат. номер: | CSB-PA761682 | Цена (с НДС 20%): | по запросу | В корзину | Наименование: Phospho-ERBB2 (Tyr1112) Antibody. Примечание: дополнительная информация (на английском языке). |
|